1

2
Luecking Ulrich, Siemeister Gerhard, Jautelat Rolf: (De) Sulfoximide als proteinkinaseinhibitoren, (En) Sulphoximides as protein kinase inhibitors. Bayer Schering Pharma Aktiengesellschaft, Luecking Ulrich, Siemeister Gerhard, Jautelat Rolf, March 6, 2008: WO/2008/025556 (36 worldwide citation)

(EN) The invention relates to carbamoylsulphoximides as protein kinase inhibitors of the general formula (I).(DE) Die Erfindung betrifft Carbamoyl-Sulfoximide als Proteinkinaseinhibitoren der allgemeinen Formel (I).


3

4
Jautelat Rolf, Siemeister Gerhard, Luecking Ulrich: (De) Neuartige hetaryl-phenylendiamin-pyrimidine als proteinkinaseinhibitoren zur behandlung von krebs, (En) Novel hetaryl-phenylene-diamine pyrimidine as protein kinase inhibitors. Bayer Schering Pharma Aktiengesellschaft, Jautelat Rolf, Siemeister Gerhard, Luecking Ulrich, June 26, 2008: WO/2008/074515 (29 worldwide citation)

(EN) The invention relates to novel hetaryl-phenylene-diamine pyrimidines and the structurally related oxygen and sulfur analogs thereof having the common formula (I). The invention further relates to a method for the production thereof and to the use thereof as a pharmaceutical.(DE) Die Erfindung b ...


5

6
Liu Bing, Light David, Wang Zhuozhi, Schneider Douglas: Monospecific and multispecific antibodies and method of use. Bayer Schering Pharma Aktiengesellschaft, Liu Bing, Light David, Wang Zhuozhi, Schneider Douglas, BAYER SCHERING PHARMA AKTIENGESELLSCHAFT, February 19, 2009: WO/2009/021754 (23 worldwide citation)

This invention relates to monospecific and multispecific antibodies that may be utilized for the diagnosis and treatment of various diseases. In addition, these antibodies may be modified by protease cleavage. Protease control or regulation may be provided by a protease site located in, for example, ...


7
Hölder Swen, Zülch Armin, Bär Thomas, Maier Thomas, Zimmermann Astrid, Beckers Thomas, Gekeler Volker, Joshi Hemant, Munot Yogesh, Bhise Umesh, Chavan Sunil, Shivatare Sachin, Patel Sarvesh, Gore Vikas: Fused imidazoles for cancer treatment. Bayer Schering Pharma Aktiengesellschaft, Hölder Swen, Zülch Armin, Bär Thomas, Maier Thomas, Zimmermann Astrid, Beckers Thomas, Gekeler Volker, Joshi Hemant, Munot Yogesh, Bhise Umesh, Chavan Sunil, Shivatare Sachin, Patel Sarvesh, Gore Vikas, February 19, 2009: WO/2009/021990 (22 worldwide citation)

Compounds of Formula (I), a tautomer or stereoisomer thereof, or a salt thereof,wherein ring B and the imidazole to which it is fused, R4, R6 and R7 have the meanings as given in the description and the claims, are effective inhibi tors of the Pi3K/Akt pathway.


8
Ulrich Speck, Brunn Scheller: Preparation for the prophylaxis of restenosis. Bayer Schering Pharma Aktiengesellschaft, Millen White Zelano & Branigan P C, July 6, 2010: US07750041 (19 worldwide citation)

The invention relates to a preparation for restenosis prevention. The preparations for restenosis prevention known as yet do not reach sufficient active agent concentrations in the affected sections of the vascular walls as higher doses cause undesirable side effects. The present invention is a prep ...


9
Cristina Alonso Alija, Michael Harter, Michael Hahn, Josef Pernerstorfer, Stefan Weigand, Johannes Peter Stasch, Frank Wunder: Substituted aminodicarboxylic acid derivatives having pharmaceutical properties. Bayer Schering Pharma Aktiengesellschaft, Edwards Angell Palmer & Dodge, Nicholas J DiCeglie Jr, Barry Kramer, April 27, 2010: US07705043 (19 worldwide citation)

The invention relates to compounds of formula (I) and their salts and stereoisomers in which the variables are as defined in the description and claims, for producing medicaments used in the treatment of cardiovascular and other diseases. Such compounds, processes for preparing them, compositions co ...


10
BADER BENJAMIN: Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors. BAYER SCHERING PHARMA AKTIENGESELLSCHAFT, March 10, 2011: WO/2011/026579 (18 worldwide citation)

The present invention relates to substituted aminoquinoxaline compounds of general formula (I) in which (II), R2, R3, R4, R6, R7, n and m are as given in the description and in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compoun ...